Related Experiment Video
Updated: May 13, 2026

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Recent compounds for immunosuppression and experimental therapies for acute graft-versus-host disease
Maria Michael1, Avichai Shimoni, Arnon Nagler
1Hematology Division & Bone Marrow Transplantation, Sheba Medical Center, Tel Hashomer, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. mariathmichael@gmail.com
Abstract:
Acute graft-versus-host disease (GVHD) is a major source of morbidity and mortality after allogeneic stem cell transplantation. Therapy of established acute GVHD depends heavily on corticosteroids, which have limited efficacy and are considerably toxic. It is still a matter of debate whether there is an alternative therapy to corticosteroids. Second-line treatment for acute GVHD after failure of steroidsis not well substantiated due to the lack of controlled studie This review examines the current treatment for acute GVHD, as well as novel therapeutics, such as cellular approlaches (e.g., adoptive transfer of mesenchymal stem cellt) and , enhancement of regulatory T cells (e.g., photopheresis). These approaches avoid the toxicity of generalized immunosuppression and are likely to play a prominent futurer ole in acute GVHD therapy.
Related Concept Videos
Cell-mediated Immune Responses
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
